Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
ShapeTX is leveraging AI to discover RNA medicines that will be effective, safe, and easy to manufacture. ShapeTX’s platform enables the design of innovative medicines across a wide range of diseases, including genetic disorders and debilitating conditions, such as Alzheimer’s, Parkinson’s, and other genetic diseases.
“We started ShapeTX with the vision of creating the next generation of medicine using RNA and AI to repair the genetic causes of disease,” said Francois Vigneault, PhD., co-founder and Chief Executive Officer of ShapeTX. “We’re thrilled that Fierce Biotech has recognized our momentum in the field of programmable RNA medicine and I want to thank the entire ShapeTX team for their dedication and passion to make it all come to life.”
